DDInter1083 DDInter832
Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018.
A trihydroxy sugar alcohol that is an intermediate in carbohydrate and lipid metabolism.
Lofexidine {u} (Compound) resembles {v} (Compound) Apraclonidine
Lofexidine {u} (Compound) binds {v} (Gene) ADRA2A
Lofexidine {u} (Compound) upregulates {v} (Gene) HMGA2
Lofexidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Abarelix
Lofexidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Degarelix
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Ribociclib
Lofexidine {u} may lead to a major life threatening interaction when taken with {v} Toremifene
Lofexidine (Compound) resembles Apraclonidine (Compound)
Lofexidine (Compound) binds ADRA2A (Gene)
Lofexidine (Compound) upregulates HMGA2 (Gene)
Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix
Lofexidine may lead to a major life threatening interaction when taken with Ribociclib
Lofexidine may lead to a major life threatening interaction when taken with Toremifene